Indole Analogs as Novel Treatments for OCD

吲哚类似物作为强迫症的新疗法

• 批准号: 6443024
• 负责人: HOWARD P SARD
• 金额: $ 10.92万
• 依托单位: ORGANIX, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-01 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6443024
• 关键词: 5 methoxy N,N dimethyltryptamine; drug design /synthesis /production; drug screening /evaluation; indoles; laboratory mouse; mental disorder chemotherapy; nonhuman therapy evaluation; obsessive compulsive disorder; psychopharmacology; receptor binding

DESCRIPTION (provided by applicant): Obsessive Compulsive Disorder (OCD) is a serious mental illness that affects millions of people throughout the world. Existing therapies for OCD show limited efficacy, can possess troubling side effects, and often require long-term treatment. Discovery of a new treatment for OCD would have considerable scientific value and commercial value. The hallucinogen psilocybin has shown preliminary efficacy against OCD, however even if further research on this compound is positive, FDA approval for psilocybin could be problematic. In Phase One we propose to synthesize carefully selected psilocybin analogs. The pharmacology of these compounds will be evaluated both in vitro and in vivo. From this project we specifically aim to discover one or more psilocybin analogs showing efficacy in an animal model for OCD comparable to that of the existing therapies. Such a result will strongly support continuation in Phase Two. The long-term goal of this project is to discover new, improved treatments for OCD. PROPOSED COMMERCIAL APPLICATION: Discovery of a novel, improved therapy for obsessive compulsive disorder could alleviate suffering for many people worldwide and would have very substantial commercial potential.

描述（由申请人提供）： 强迫症 (OCD) 是一种 影响全世界数百万人的严重精神疾病。 现有的强迫症疗法显示出有限的疗效，并且可能具有令人不安的一面 的影响，并且往往需要长期治疗。发现新疗法 对于强迫症来说将具有相当大的科学价值和商业价值。这 然而，致幻剂裸盖菇素已显示出对强迫症的初步功效 即使对该化合物的进一步研究是积极的，FDA 也会批准 裸盖菇素可能有问题。在第一阶段，我们建议综合 精心挑选的裸盖菇素类似物。这些化合物的药理学 可以在体外和体内进行评估。从这个项目中，我们的具体目标是 发现一种或多种在动物模型中显示功效的裸盖菇素类似物 对于强迫症的治疗效果与现有疗法相当。这样的结果将会 强烈支持第二阶段的继续。本项目的长期目标 是发现新的、改进的强迫症治疗方法。 拟议的商业应用：发现一种新颖的、改进的强迫症疗法可以减轻全世界许多人的痛苦，并且具有非常巨大的商业潜力。